CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting

Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)

Published: March 1, 2025

Natural killer cells, integral to the innate immune response, exhibit inherent capacity identify and eliminate cancer cells without prior exposure, positioning them as prime candidates for immunotherapeutic strategies. Chimeric antigen receptor-engineered natural (CAR-NK) obviate requirement human leukocyte compatibility, simplifying personalized schedules facilitating manufacture of off-the-shelf products. In addition, CAR-NK cell therapy possesses lower risk cytokine release syndrome neurotoxicity, benefitting patients with higher security. Nevertheless, is also confronted challenges, including but not limited short lifespan restrictions from tumor microenvironment. Here, we summarized latest advancements in preclinical investigations clinical trials 2024 ASH Annual Meeting.

Language: Английский

Emerging Role of Chimeric Antigen Receptor-Natural Killer Cells for the Treatment of Hematologic Malignancies

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1454 - 1454

Published: April 26, 2025

The clinical use of T lymphocytes engineered with chimeric antigen receptors (CARs) has revolutionized the treatment patients refractory or relapsed hematological malignancies. CAR natural killer (CAR-NK) cells are NK CARs to specifically target cell antigens expressed on membrane tumor cells. CAR-NK could offer some advantages respect CAR-T cells, related their specific and innate anti-tumor activity, availability as an "off shelf" cellular therapy, reduced costs, improved safety. Promising efficacy CAR-Nk therapy was observed in trials based However, date, experience been preliminary, evaluation only a limited number patients. Furthermore, by short persistence these suboptimal cytotoxic activity preparations. Therefore, studies enrollment is required carefully assess confirm safety malignancies compare allogeneic

Language: Английский